Baird Medical Investment Holdings Limited (BDMD)

Baird Medical Investment Holdings Limited specializes in developing and selling microwave ablation medical devices for minimally invasive tumor treatment in China. Their devices target a range of benign and malignant tumors, offering a localized treatment option.

51/100 AI Score MCap 48M Vol 211K

Company Overview

CEOHaimei Wu
Employees148
HeadquartersGuangzhou, CN
IPO Year2021

Baird Medical Investment Holdings Limited pioneers minimally invasive tumor treatment in China with innovative microwave ablation technology, targeting a significant market opportunity in benign and malignant tumor therapy, but faces challenges in profitability and market penetration given its negative P/E ratio of -7.66 and small market cap of $0.03B.

Investment Thesis

Investing in Baird Medical presents a high-risk, high-reward opportunity. The company's focus on minimally invasive tumor treatment aligns with a growing trend in healthcare, potentially driving demand for its microwave ablation devices. The high gross margin of 86.9% indicates strong pricing power and efficient production. However, the negative P/E ratio of -7.66 and small market capitalization of $0.03B highlight significant financial challenges. Key to the investment thesis is Baird Medical's ability to achieve profitability and scale its operations within the Chinese market. Upcoming regulatory approvals and successful market penetration could serve as major catalysts. Investors should closely monitor the company's financial performance and progress in expanding its market share.

Key Highlights

  • High Gross Margin: Baird Medical boasts a gross margin of 86.9%, indicating efficient production and strong pricing power.
  • Minimally Invasive Focus: The company specializes in microwave ablation, a growing trend in tumor treatment.
  • Chinese Market Focus: Baird Medical targets the large and growing Chinese market for medical devices.
  • Negative P/E Ratio: The company has a P/E ratio of -7.66, reflecting current unprofitability.
  • Small Market Cap: With a market capitalization of $0.03B, Baird Medical is a micro-cap company with associated risks and potential for high growth.

Competitors

Strengths

  • Specialized in microwave ablation technology
  • Focus on minimally invasive tumor treatment
  • Established presence in the Chinese market
  • High gross margin (86.9%)

Weaknesses

  • Small market capitalization ($0.03B)
  • Negative P/E ratio (-7.66) indicating unprofitability
  • Limited geographic reach (primarily China)
  • Dependence on regulatory approvals

Catalysts

  • Upcoming: Regulatory approvals for new microwave ablation devices.
  • Ongoing: Expansion of sales and distribution network in China.
  • Ongoing: Strategic partnerships with hospitals and research institutions.
  • Ongoing: Increasing awareness and adoption of minimally invasive tumor treatment.

Risks

  • Potential: Failure to obtain regulatory approvals for new products.
  • Ongoing: Intense competition from established medical device companies.
  • Potential: Economic downturn in China impacting healthcare spending.
  • Ongoing: Dependence on a single geographic market (China).
  • Potential: Product liability claims.

Growth Opportunities

  • Market Penetration in China: The Chinese market for minimally invasive tumor treatment is vast and growing. Baird Medical has the opportunity to expand its market share by increasing its sales and distribution network, targeting hospitals and clinics across China. Successful penetration could significantly boost revenue and profitability. Timeline: Ongoing.
  • Expansion of Product Portfolio: Baird Medical can develop new microwave ablation devices for treating a wider range of tumors and conditions. This could involve investing in research and development to create innovative products that address unmet medical needs. A broader product portfolio would enhance the company's competitive position. Timeline: 2-3 years.
  • International Expansion: While currently focused on China, Baird Medical could explore opportunities to expand into other international markets. This would require adapting its products to meet local regulatory requirements and establishing partnerships with distributors in new regions. International expansion could diversify revenue streams and reduce reliance on the Chinese market. Timeline: 3-5 years.
  • Strategic Partnerships: Collaborating with hospitals, research institutions, and other medical device companies could accelerate Baird Medical's growth. Partnerships could provide access to new technologies, markets, and distribution channels. Strategic alliances could also enhance the company's credibility and reputation. Timeline: Ongoing.
  • Regulatory Approvals: Obtaining regulatory approvals for its existing and new products is crucial for Baird Medical's growth. Successful navigation of the regulatory landscape will allow the company to commercialize its products and generate revenue. Streamlined regulatory processes and favorable government policies could accelerate this process. Timeline: Ongoing.

Opportunities

  • Expansion into new geographic markets
  • Development of new microwave ablation devices
  • Strategic partnerships with hospitals and research institutions
  • Increasing demand for minimally invasive procedures

Threats

  • Competition from larger medical device companies
  • Regulatory hurdles and delays
  • Economic slowdown in China
  • Technological advancements that could render existing products obsolete

Competitive Advantages

  • Proprietary microwave ablation technology
  • Established presence in the Chinese market
  • Specialized expertise in minimally invasive tumor treatment
  • Strong relationships with hospitals and clinics in China

About

Founded in 2012 and headquartered in Guangzhou, China, Baird Medical Investment Holdings Limited is dedicated to the development and commercialization of microwave ablation medical devices. These devices offer a minimally invasive approach to treating various types of tumors, both benign and malignant. The company's product portfolio is designed to address conditions such as thyroid nodules, liver cancer, lung cancer, and breast lumps, providing an alternative to traditional surgical methods. Baird Medical focuses on the Chinese market, aiming to meet the growing demand for advanced medical technologies in tumor treatment. By offering minimally invasive solutions, Baird Medical seeks to reduce patient trauma, shorten recovery times, and improve overall treatment outcomes. The company operates with a team of 148 employees, focusing on innovation and market expansion within the competitive medical device landscape. Despite a high gross margin of 86.9%, Baird Medical currently faces profitability challenges, reflected in its negative profit margin of -10.0%.

What They Do

  • Develops microwave ablation medical devices.
  • Sells microwave ablation medical devices.
  • Focuses on minimally invasive tumor treatment.
  • Targets benign and malignant tumors.
  • Treats thyroid nodules, liver cancer, lung cancer, and breast lumps.
  • Offers an alternative to traditional surgical methods.

Business Model

  • Develops and manufactures microwave ablation devices.
  • Sells devices directly to hospitals and clinics.
  • Generates revenue from device sales.
  • Provides training and support to medical professionals.

Industry Context

Baird Medical operates within the medical device industry, specifically focusing on the market for minimally invasive tumor treatment. This market is experiencing growth driven by technological advancements and patient preference for less invasive procedures. The competitive landscape includes both domestic Chinese companies and international players. Competitors such as BDSX, BEAT, CTSO, ECOR, and FGEN also operate in the broader medical device space, though not all focus specifically on microwave ablation. Baird Medical's success depends on its ability to differentiate its technology, navigate regulatory hurdles, and establish a strong market presence in China.

Key Customers

  • Hospitals in China
  • Clinics in China
  • Medical professionals specializing in oncology
  • Patients seeking minimally invasive tumor treatment
AI Confidence: 71% Updated: 2/9/2026

Financials

Chart & Info

Price Chart

Baird Medical Investment Holdings Limited (BDMD) stock price: $1.30 (-0.04, -2.99%)

Why Bull

  • •Recent insider buying could signal confidence in BDMD's future prospects, suggesting those closest to the company see value.
  • •Positive community sentiment indicates growing belief in BDMD's potential, possibly fueled by recent news or developments.
  • •Market perception seems to be improving, with more investors viewing BDMD as a viable player in its sector.
  • •Bullish community views are highlighting BDMD's innovative approach, potentially attracting more attention and investment.

Why Bear

  • •Lack of recent significant news might lead to stagnation, as the market seeks fresh catalysts for growth.
  • •Bearish community views express concerns about the long-term viability of BDMD's business model.
  • •Insider activity, even if positive overall, might have some sales mixed in, raising questions about internal expectations.
  • •Market perception might be overly optimistic, failing to account for potential risks and challenges facing BDMD.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
210,968

Rationale

AI-generated technical analysis for BDMD including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Baird Medical Investment Holdings Limited (BDMD) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for BDMD.

Make a Prediction

Set your price target for Baird Medical Investment Holdings Limited (BDMD), choose a timeframe, and track your prediction accuracy.

Current price: $1.30

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDMD.

Price Targets

Wall Street price target analysis for BDMD.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

50.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 10/100

    Gross margin of 86.9% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates BDMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Baird Medical Investment Holdings Limited do?

Baird Medical Investment Holdings Limited is a medical device company specializing in the development and sale of microwave ablation technology for minimally invasive tumor treatment. The company's devices are used to treat a variety of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. By offering minimally invasive solutions, Baird Medical aims to provide patients with less traumatic treatment options, shorter recovery times, and improved overall outcomes, primarily focusing on the Chinese healthcare market.

Is BDMD stock a good buy?

Evaluating BDMD requires careful consideration. The company's high gross margin of 86.9% suggests strong pricing power, and its focus on minimally invasive tumor treatment aligns with a growing market trend. However, the negative P/E ratio of -7.66 and small market capitalization of $0.03B indicate significant financial risks. Potential investors should assess the company's ability to achieve profitability, expand its market share in China, and navigate regulatory hurdles before making an investment decision. The stock is speculative and suitable for investors with a high-risk tolerance.

What are the main risks for BDMD?

Baird Medical faces several key risks. Intense competition from larger, more established medical device companies poses a significant threat. Regulatory hurdles and potential delays in obtaining approvals for new products could impede growth. The company's reliance on the Chinese market makes it vulnerable to economic downturns and changes in government policies. Furthermore, product liability claims and technological advancements that could render existing products obsolete represent ongoing risks that investors should carefully consider.

Is BDMD a good stock to buy?

Whether BDMD is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the BDMD MoonshotScore?

The MoonshotScore for BDMD is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is BDMD data updated?

BDMD stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BDMD is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for BDMD?

Growth catalysts for Baird Medical Investment Holdings Limited (BDMD) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Baird Medical Investment Holdings Limited's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are BDMD's main competitors?

Baird Medical Investment Holdings Limited (BDMD) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BDMD has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about BDMD?

Wall Street analyst coverage for BDMD includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is BDMD's market cap?

Market capitalization (market cap) for BDMD is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BDMD's current market cap alongside enterprise value and other valuation metrics.

How has BDMD stock performed recently?

BDMD's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BDMD's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in BDMD?

Key risk categories for BDMD include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BDMD's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling BDMD?

Insider trading activity for BDMD tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is BDMD a good stock for beginners?

Baird Medical Investment Holdings Limited (BDMD) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is BDMD for first-time investors?

Every stock carries risk, including Baird Medical Investment Holdings Limited (BDMD). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BDMD.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • The company's financial performance is volatile and subject to market conditions.
Data Sources
profilefundamentalsexistingCopy